Table 4.
Comparison of celiac antibodies between the psoriasis and control groups according to MTX and biological agent use.
| Methotrexate use a n = 22 | Control group n = 65 | Biologic agent useb n = 19 | Control group n = 65 | p | ||
|---|---|---|---|---|---|---|
| Antigliadin IgA, median (IQR:25–75) | 2.7 (2.1–4.5) | 3.5 (2.3–5.4) | 0.51 | 2.4 (2.0–4.6) | 3.5 (2.3–5.4) | 0.65 |
| Antigliadin IgG, median (IQR:25–75) | 3.0 (2.0–5.7) | 4.2 (2.7–5.4) | 0.23 | 3.2 (2.1–5.2) | 4.2 (2.7–5.4) | 0.40 |
| Anti-TTG IgA, median (IQR:25–75) | 2.3 (1.2–4.6) | 3.2 (1.3–5.4) | 0.11 | 3.1 (1.2–4.1) | 3.2 (1.3–5.4) | 0.54 |
| Anti-TTG IgG, median (IQR:25–75) | 2.1 (1.3–3.5) | 3.2 (1.1–5.1) | 0.17 | 4.1 (1.0–5.6) | 3.2 (1.1–5.1) | 0.49 |
IQR; interquartile range, TTG; tissue transglutaminase.
a
In this group, 15 patients received only methotrexate, and seven patients received combined topical treatment with methotrexate.
b
All patients in this group were treated with an anti-TNFα or anti-IL17A agent alone.